XVII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2024 ECTRIMS Congress (II)

Introduction: The XVII edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 4-5 October 2024 in Madrid. This event was attended by Spanish neurologists specialized in multiple sclerosis (MS), who presented a summary of the most relevan...

ver descrição completa

Detalhes bibliográficos
Autores: Fernández, Óscar, Arés, Adrián, Agüera, Eduardo, Aladro, Yolanda, Alonso, Ana, Arroyo, Rafael, Brieva, Luis, Calles, Carmen, Belén Caminero, Ana, Castillo Triviño, Tamara, Costa Frossard, Lucienne, Eichau, Sara, Ángel Hernández, Miguel, Landete, Lamberto, Llaneza, Miguel, Llufriu, Sara, Meca Lallana, José E., Meca Lallana, Virginia, Moral, Ester, Oreja Guevara, Celia, María Prieto, José, Romero Pinel, Lucía María, Vilaseca, Andreu, Rodríguez Antigüedad, Alfredo
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2026
País:España
Recursos:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/228189
Acesso em linha:https://hdl.handle.net/2445/228189
Access Level:acceso abierto
Palavra-chave:Esclerosi múltiple
Malalties cerebrovasculars
Revisions mèdiques
Multiple sclerosis
Cerebrovascular disease
Periodic health examinations
Descrição
Resumo:Introduction: The XVII edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 4-5 October 2024 in Madrid. This event was attended by Spanish neurologists specialized in multiple sclerosis (MS), who presented a summary of the most relevant advances discussed at the ECTRIMS congress, held days before in Copenhagen.Aim: To summarize the main new findings in clinical research on MS.Content and Conclusions: The immunological changes throughout life and in response to MS treatments were analyzed. The impact of aging was also discussed, along with new developments related to symptomatic treatments, physical exercise, fatigue, and sleep disorders. Emphasis was placed on addressing ongoing challenges in measuring therapeutic failure and managing treatments for secondary progressive MS. Additionally, data from registries and real-world studies were presented, including new analyses on cladribine, highlighting the need to collect safety information. Regarding immune reconstitution therapies, mechanisms of action and the immune system's reconstitution process after treatment were explored. Finally, regarding therapeutic innovations, the first results from chimeric antigen receptor (CAR)-T cell therapy studies in MS were reported, representing a promising advancement in disease management.

Registos relacionados